VJHemOnc is committed to improving our service to you

ICML 2019 | Venetoclax: undetectable peripheral blood MRD status as a therapeutic goal in R/R CLL

VJHemOnc is committed to improving our service to you

Sasanka Handunnetti

Sasanka Handunnetti, MBBS, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the use of an undetectable peripheral blood MRD status as a therapeutic goal in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated with venetoclax in a retrospective analysis. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter